Mark Plavsic
Direttore Tecnico/Scientifico/R&S presso AURA BIOSCIENCES, INC.
Patrimonio netto: 1 M $ in data 30/06/2024
Profilo
Il dott. Mark Plavsic è un direttore tecnico presso Fate Therapeutics, Inc. Il Dr. Plavsic è stato precedentemente impiegato come Chief Technical Officer presso Lysogene SA e Head- Process Development & Manufacturing presso Torque Therapeutics, Inc. Si è laureato all'Università di Belgrado e ha conseguito il dottorato all'Università di Belgrado.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
AURA BIOSCIENCES INC
0.26% | 15/03/2024 | 128 515 ( 0.26% ) | 971 573 $ | 30/06/2024 |
FATE THERAPEUTICS, INC.
0.11% | 10/01/2023 | 123 705 ( 0.11% ) | 405 752 $ | 30/06/2024 |
Posizioni attive di Mark Plavsic
| Società | Posizione | Inizio |
|---|---|---|
| AURA BIOSCIENCES, INC. | Direttore Tecnico/Scientifico/R&S | 02/10/2023 |
TeraPore Technologies, Inc.
 TeraPore Technologies, Inc. Chemicals: SpecialtyProcess Industries TeraPore Technologies, Inc. develops cutting-edge membrane technologies for high-permeability, high-resolution nanofiltration. The company was founded by Rachel Dorin in 2013 and is headquartered in | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Mark Plavsic
| Società | Posizione | Fine |
|---|---|---|
| FATE THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | 06/03/2023 |
Genzyme Therapeutics Ltd.
 Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Corporate Officer/Principal | - |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Torque Therapeutics, Inc.
 Torque Therapeutics, Inc. BiotechnologyHealth Technology Torque Therapeutics, Inc. develops immunotherapies to address cancers focused on the specific modulation of immune cell subsets. The company was founded by Bart Henderson, Ulrik B. Nielsen, Darrell J. Irvine, and Thomas Lars Andresen and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
| LYSOGENE | Direttore Tecnico/Scientifico/R&S | - |
Formazione di Mark Plavsic
| University of Belgrade | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| LYSOGENE | Commercial Services |
| FATE THERAPEUTICS, INC. | Health Technology |
| AURA BIOSCIENCES, INC. | Health Technology |
| Aziende private | 4 |
|---|---|
Torque Therapeutics, Inc.
Torque Therapeutics, Inc. BiotechnologyHealth Technology Torque Therapeutics, Inc. develops immunotherapies to address cancers focused on the specific modulation of immune cell subsets. The company was founded by Bart Henderson, Ulrik B. Nielsen, Darrell J. Irvine, and Thomas Lars Andresen and is headquartered in Cambridge, MA. | Health Technology |
TeraPore Technologies, Inc.
TeraPore Technologies, Inc. Chemicals: SpecialtyProcess Industries TeraPore Technologies, Inc. develops cutting-edge membrane technologies for high-permeability, high-resolution nanofiltration. The company was founded by Rachel Dorin in 2013 and is headquartered in | Process Industries |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- Mark Plavsic
